middle.news
Recce Pharmaceuticals Secures A$85M R&D Tax Incentive Boost for Global Antibiotic Fight
9:57am on Tuesday 16th of December, 2025 AEDT
•
Healthcare
Read Story
Recce Pharmaceuticals Secures A$85M R&D Tax Incentive Boost for Global Antibiotic Fight
9:57am on Tuesday 16th of December, 2025 AEDT
Key Points
A$85 million Advanced Overseas Finding awarded for R&D expenditure
43.5% R&D tax rebate extended to overseas activities for three years
Supports Phase 3 Diabetic Foot Infection clinical trial in Indonesia
Validates Recce’s global synthetic anti-infective development strategy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE